Press Releases OmRx Oncology Initiates Phase 2 Trial of Oral PD-L1 Inhibitor OX-4224 in NSCLC Checkpoint inhibitors targeting the programmed cell death 1 (PD-1)/programmed cell death 1 ligand… May 8, 2025
Press Releases OmRx Oncology Launches to Advance Investigational Oral Checkpoint Inhibitor Designed to Increase Access to Cancer Immunotherapy Worldwide Checkpoint inhibitors targeting the programmed cell death 1 (PD-1)/programmed cell death 1 ligand… September 12, 2024
